Actively Recruiting
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
Led by Roswell Park Cancer Institute · Updated on 2026-03-17
99
Participants Needed
1
Research Sites
514 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This phase I/II trial studies the side effects of pulmonary suffusion in controlling minimal residual disease in patients with sarcoma or colorectal carcinoma that has spread to the lungs. Pulmonary suffusion is a minimally invasive delivery of chemotherapeutic agents like cisplatin to lung tissues. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pulmonary suffusion may also be useful in avoiding later use of drugs by vein that demonstrate no effect on tumors when delivered locally.
CONDITIONS
Official Title
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have metastatic tumors in the lungs from soft tissue sarcoma, osteosarcoma, or colorectal carcinoma
- ECOG performance status of 2 or less
- Hemoglobin greater than 8.0 g/L
- Granulocytes more than 1,500 per microliter
- Platelets equal to or greater than 100,000 per microliter
- Creatinine clearance of at least 30 mL/min
- Lung metastases that can be surgically removed or treated with ablation
- Lung function measures: FEV1, DLCO, and vital capacity each at least 50% of predicted
- Oxygen saturation above 88% at rest and during walking
- Able to walk at least 50% of the expected distance in six minutes
- Surgeon confirms pulmonary suffusion is technically possible
- Borg Dyspnea score less than 5
- Primary tumor is controlled or stable according to clinical assessment
- Women of child-bearing potential agree to use effective contraception
- Able to understand and sign informed consent
You will not qualify if you...
- Had chemotherapy or radiotherapy within 4 weeks prior to the study (6 weeks for certain drugs) or have not recovered from previous treatment side effects
- Known brain metastases
- Allergy or serious reaction to chemotherapy drugs used in the study
- Pregnant or nursing
- Unable or unwilling to follow study procedures
- Lung metastases that cannot be completely removed or ablated
- Any condition judged by the investigator to make participation unsafe or unsuitable
- Received an investigational drug within 30 days before enrollment
- Severe peripheral neuropathy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
Actively Recruiting
Research Team
K
Kenneth Seastedt
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here